- Home
- GLPG vs SHOO Comparison
GLPG vs SHOO Comparison
Compare GLPG & SHOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- SHOO
- Stock Information
- Founded
- GLPG 1999
- SHOO 1990
- Country
- GLPG Belgium
- SHOO United States
- Employees
- GLPG N/A
- SHOO N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- SHOO Shoe Manufacturing
- Sector
- GLPG Health Care
- SHOO Consumer Discretionary
- Exchange
- GLPG Nasdaq
- SHOO Nasdaq
- Market Cap
- GLPG 2.1B
- SHOO 2.0B
- IPO Year
- GLPG 2005
- SHOO 1993
- Fundamental
- Price
- GLPG $31.44
- SHOO $28.03
- Analyst Decision
- GLPG Sell
- SHOO Hold
- Analyst Count
- GLPG 4
- SHOO 7
- Target Price
- GLPG $25.33
- SHOO $27.83
- AVG Volume (30 Days)
- GLPG 345.0K
- SHOO 1.8M
- Earning Date
- GLPG 07-23-2025
- SHOO 07-30-2025
- Dividend Yield
- GLPG N/A
- SHOO 2.94%
- EPS Growth
- GLPG N/A
- SHOO N/A
- EPS
- GLPG N/A
- SHOO 1.28
- Revenue
- GLPG $323,674,692.00
- SHOO $2,319,527,000.00
- Revenue This Year
- GLPG N/A
- SHOO $13.01
- Revenue Next Year
- GLPG N/A
- SHOO $9.15
- P/E Ratio
- GLPG N/A
- SHOO $22.37
- Revenue Growth
- GLPG 5.43
- SHOO 7.97
- 52 Week Low
- GLPG $22.36
- SHOO $19.05
- 52 Week High
- GLPG $33.86
- SHOO $50.01
- Technical
- Relative Strength Index (RSI)
- GLPG 47.00
- SHOO 60.22
- Support Level
- GLPG $31.39
- SHOO $26.05
- Resistance Level
- GLPG $32.43
- SHOO $28.92
- Average True Range (ATR)
- GLPG 0.77
- SHOO 0.96
- MACD
- GLPG -0.22
- SHOO 0.21
- Stochastic Oscillator
- GLPG 7.22
- SHOO 79.82
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.